Fulminant type 1 diabetes mellitus following SARS-CoV-2 infection: a case report

被引:0
|
作者
Zhong, Xinyuan [1 ,2 ]
Dong, Shuqin [3 ]
Chen, Ming [1 ]
Lu, Yu [1 ]
机构
[1] Nanjing Med Univ, Affiliated Taizhou Peoples Hosp, Taizhou Sch Clin Med, Dept Endocrinol, 366 Taihu Rd, Taizhou 225300, Peoples R China
[2] Dalian Med Univ, Grad Sch, Dalian 116044, Liaoning, Peoples R China
[3] Nanjing Med Univ, Affiliated Taizhou Peoples Hosp, Taizhou Sch Clin Med, Dept Crit Care Med, 366 Taihu Rd, Taizhou 225300, Peoples R China
关键词
Fulminant type 1 diabetes mellitus; Coronavirus disease 2019 (COVID-19); SARS-CoV-2; Case report;
D O I
10.1007/s13410-024-01354-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveRecent evidence indicates a potential link between SARS-CoV-2 infection and disturbances in glucose metabolism. Several cases of new-onset diabetes, including fulminant type 1 diabetes mellitus (FT1DM), have been reported following SARS-CoV-2 infection or vaccination.Methods and resultsIn this case report, we present the clinical course and outcomes of a middle-aged male who developed sudden hyperglycemia and diabetic ketoacidosis following SARS-CoV-2 infection. The patient had no previous history of diabetes and no family history of this disease. Upon admission, the patient had a normal glycohemoglobin level, but the fasting and postprandial C-peptide levels were found to be extremely low, suggesting severe insulin deficiency. These findings were consistent with the diagnosis of FT1DM. The patient was promptly treated with insulin therapy, leading to a rapid improvement in ketoacidosis and hyperglycemia. Despite the successful management of acute complications, the patient's pancreatic beta cell function did not recover. As a result, the patient received treatment with insulin therapy after being discharged. The first follow-up visit revealed stable blood glucose control, but still with extremely low C-peptide levels.ConclusionsSARS-CoV-2 infection may lead to the development of FT1DM. This case report raises awareness of early recognition and therapy for FT1DM during the COVID-19 pandemic.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Fulminant Type 1 Diabetes Mellitus after SARS-CoV-2 Vaccination: A Case Report
    Lin, Rong
    Lin, Yu-Wei
    Chen, Mei-Hsiu
    VACCINES, 2022, 10 (11)
  • [2] Case report: Fulminant type 1 diabetes following paucisymptomatic SARS-CoV-2 infection during late pregnancy
    Zhou, Lingling
    Qu, Huanjia
    Zhang, Qiuling
    Hu, Jinhua
    Shou, Lan
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [3] Fulminant fungal endogenous endophthalmitis following SARS-CoV-2 infection: A case report
    Jain, Mukesh
    Brar, Anand Singh
    Rath, Suryasnata
    Kelgaokar, Anup
    Behera, Himansu Sekhar
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2022, 70 (05) : 1819 - 1821
  • [4] A case of Graves' disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination
    Patrizio, Armando
    Ferrari, Silvia Martina
    Antonelli, Alessandro
    Fallahi, Poupak
    JOURNAL OF AUTOIMMUNITY, 2021, 125
  • [5] Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination
    Aydogan, Berna Imge
    Unluturk, Ugur
    Cesur, Mustafa
    ENDOCRINE, 2022, 78 (01) : 42 - 46
  • [6] The relationship between SARS-CoV-2 infection and type 1 diabetes mellitus
    Debuysschere, Cyril
    Nekoua, Magloire Pandoua
    Alidjinou, Enagnon Kazali
    Hober, Didier
    NATURE REVIEWS ENDOCRINOLOGY, 2024, 20 (10) : 588 - 599
  • [7] Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination
    Mungmunpuntipantip, Rujittika
    Wiwanitkit, Viroj
    ENDOCRINE, 2022, 78 (03) : 641 - 641
  • [8] Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination
    Berna İmge Aydoğan
    Uğur Ünlütürk
    Mustafa Cesur
    Endocrine, 2022, 78 : 42 - 46
  • [9] Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination
    Rujittika Mungmunpuntipantip
    Viroj Wiwanitkit
    Endocrine, 2022, 78 : 641 - 641
  • [10] A case of new-onset Fulminant type 1 diabetes after secondary SARS-CoV-2 infection
    Wang, Jie
    Huang, Yiwen
    Tao, Feng
    HELIYON, 2024, 10 (09)